CRC Cohort of Ph 2 Trial of PDS01ADC Met Criteria for Expansion to Stage 2 Following Positive Stage 1 Results July 15, 2025
XTANDI + Leuprolide combo Significantly Improves Survival Outcomes in Men with Non-Metastatic HSPC with High-Risk Biochemical Recurrence July 15, 2025
SIR-Spheres® Y-90 Resin Microspheres Receive FDA Approval for the Treatment of Unresectable HCC July 15, 2025
Enrollment completed in Ph 3 UTOPIA Trial of UGN-103 for the Treatment of Recurrent Low-Grade Intermediate-Risk NMIBC July 15, 2025
Encouraging Response Rates Announced from Ph 1b Trial of the Azer-cel Allogeneic CAR T in 3L+ DLBCL July 15, 2025
NDA submitted for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer July 15, 2025
European Commission Approves TEVIMBRA® in Combination with Chemotherapy as 1L Treatment for Nasopharyngeal Carcinoma July 15, 2025
CoRegen announced the close of a $93,390,000 million financing to advance CMC development July 15, 2025
AbbVie and Ichnos Glenmark Innovation (IGI) Announce Exclusive Global Licensing Agreement for First-in-Class CD38×BCMA×CD3 Trispecific Antibody ISB 2001 July 15, 2025
Oxford BioTherapeutics Announces Third Oncology Drug Candidate from Boehringer Ingelheim Collaboration Selected to Advance into IND-Enabling Studies July 15, 2025
Biocytogen Enters into Antibody Licensing Agreement with BeOne Medicines to Accelerate Innovative Drug Development July 15, 2025
First patient dosed in the Ph 1 portion of Ph 1/2 trial of AVZO-1418/DB-1418 in patients with advanced solid tumors July 15, 2025
Early Efficacy Data Reported from First TNBC Patient Receiving Paxalisib Combination Regimen achieving >50% Reduction in CTCs in Ph 1b Trial July 15, 2025
Pelareorep Survival Data in Multiple Tumors and Commitment to Registration-Enabling Studies announced July 15, 2025
Patient Achieves Sustained Complete Resolution of Lung Metastasis in Bria-OTS Metastatic Breast Cancer Study July 15, 2025
Bria-IMT Demonstrates Survival Advantage over Trodelvy® and Control Group in Metastatic Breast Cancer July 15, 2025
Real-World Data Demonstrate a 49% Response Rate for Commercial Amtagvi® in Patients with Advanced Melanoma July 15, 2025
Primary Results from Ph 2 RAMP 201 Trial of Avutometinib + Defactinib combo in Patients with Recurrent Low-Grade Serous Ovarian Cancer published in JCO July 15, 2025
End of Phase 2 Meeting with FDA scheduled for August 27, 2025 to review OST-HER2 recurrent, pulmonary metastatic osteosarcoma program July 15, 2025
Type C meeting with the FDA requested to discuss the D-MNA product development and gain further alignment on the clinical pathway July 15, 2025
